Antithymocyte Globulin (ATG)

Atgam

Near Add Your Location

Sorting 9 by

Accepting patients

Cord Blood Transplantation in Children

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Horse Anti-Thymocyte Globulin (hATG)

Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
  • White Blood Cell Stimulant
  • Steroid
  • Phase 2

Accepting patients

RAFA

A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
  • Allogeneic Stem Cell Transplant
  • Phase 2

Not yet accepting

2 Step ATG

Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Myeloablative Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Allogeneic Stem Cell Transplant

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Personalized Natural Killer Cell Therapy

Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
  • Natural Killer Cells (Allogeneic)
  • Phase 2

Accepting patients

Cytokine-Treated Veto Cells Post-Transplant

Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant
  • Allogeneic Stem Cell Transplant
  • Phase 1/2

Accepting patients

ATG Dosing for GVHD Prevention

Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Reduced Intensity Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Targeted ATG Dosing Pilot Study

Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha/Beta T-Cell and B-Cell Depletion for Patients With Hematologic Malignancies With Targeted ATG Dosing Pilot Study, IDE 13641
  • Allogeneic Stem Cell Transplant
  • Phase 0